Pharmanutra Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Pharmanutra de 19.2% y 10.4% por año respectivamente. Se prevé que el BPA crezca en un 19.1% al año. Se espera que la rentabilidad financiera sea de 27.1% en 3 años.

Información clave

19.2%

Tasa de crecimiento de los beneficios

19.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Personal Products	7.6%
Tasa de crecimiento de los ingresos	10.4%
Rentabilidad financiera futura	27.1%
Cobertura de analistas	Low
Última actualización	18 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 23

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Mar 10

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Feb 17

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Feb 01

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Jan 18

Is Pharmanutra (BIT:PHN) A Risky Investment?

Jan 04

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

Dec 22

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Dec 08

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 23

Previsiones de crecimiento de beneficios e ingresos

BIT:PHN - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	135	23	21	25	1
12/31/2025	131	22	19	23	2
12/31/2024	115	18	16	20	2
12/31/2023	101	13	-1	12	N/A
9/30/2023	94	12	-5	9	N/A
6/30/2023	93	14	-19	9	N/A
3/31/2023	88	17	-15	11	N/A
12/31/2022	83	15	-9	17	N/A
9/30/2022	79	16	-5	19	N/A
6/30/2022	76	15	10	19	N/A
3/31/2022	73	15	14	20	N/A
12/31/2021	68	14	15	20	N/A
9/30/2021	65	14	13	16	N/A
6/30/2021	60	11	12	15	N/A
3/31/2021	57	14	13	15	N/A
12/31/2020	57	14	10	12	N/A
9/30/2020	58	14	11	11	N/A
6/30/2020	58	14	7	11	N/A
3/31/2020	55	9	4	9	N/A
12/31/2019	54	8	7	12	N/A
9/30/2019	49	8	3	8	N/A
6/30/2019	50	9	7	9	N/A
3/31/2019	48	9	6	8	N/A
12/31/2018	47	9	6	6	N/A
9/30/2018	44	8	5	6	N/A
6/30/2018	41	7	5	6	N/A
3/31/2018	40	6	5	6	N/A
12/31/2017	38	6	5	6	N/A
9/30/2017	37	5	N/A	N/A	N/A
6/30/2017	35	5	N/A	N/A	N/A
3/31/2017	34	4	N/A	N/A	N/A
12/31/2016	33	4	N/A	6	N/A
12/31/2015	26	3	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (19.2% al año) de PHN es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (19.2% al año) de PHN crezcan más rápidamente que el mercado Italian (5.1% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de PHN crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (10.4% al año) de PHN crezcan más rápidamente que los del mercado Italian (3.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 10.4% al año) de PHN crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de PHN sea alta dentro de 3 años (27.1%)

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Pharmanutra Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased to €59.33

Price target increased to €50.67

Price target increased to €45.00

Recent updates

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Pharmanutra (BIT:PHN) Could Easily Take On More Debt

Third quarter 2021 earnings released: EPS €0.39 (vs €0.18 in 3Q 2020)

Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

Investor sentiment improved over the past week

Price target increased to €59.33

Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

Price target increased to €50.67

Investor sentiment improved over the past week

Price target increased to €45.00

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Upcoming dividend of €0.67 per share

Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

Full year 2020 earnings released: EPS €1.45 (vs €0.87 in FY 2019)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Is Pharmanutra (BIT:PHN) A Risky Investment?

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

New 90-day high: €33.70

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Market bids up stock over the past week

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: €28.80

Third quarter 2020 earnings released: EPS €0.18

New 90-day high: €27.20

First half earnings released

First half earnings released

New 90-day low - €22.40

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento